Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Allred

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Anticancer Research|November 1, 1992
Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniquesR Molina, D R Ciocca, A K Tandon, et al.
Breast Cancer Research and Treatment|June 28, 2005
Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancerG Arpino, D R Ciocca, H Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1994
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancerP M Ravdin, A K Tandon, D C Allred, et al.
Human Pathology|September 1, 1992
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancerD C Allred, G M Clark, R Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group StudyR M Elledge, S Green, D Ciocca, et al.
Breast Cancer Research and Treatment|January 1, 1993
The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domainS A Fuqua, D C Allred, R M Elledge, et al.
Cancer Research|January 15, 1992
Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumorsS A Fuqua, S D Fitzgerald, D C Allred, et al.
Cancer Research|August 17, 2000
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesionsS A Fuqua, C Wiltschke, Q X Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1992
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinomaD C Allred, G M Clark, A K Tandon, et al.
Virchows Archiv : an International Journal of Pathology|January 1, 1994
p53 mutations in gastric and colorectal cancers in Texas Hispanics versus AnglosB G Schneider, S G Hilsenbeck, C H Hensel, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Anticancer Research|November 1, 1992
Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniquesR Molina, D R Ciocca, A K Tandon, et al.
Breast Cancer Research and Treatment|June 28, 2005
Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancerG Arpino, D R Ciocca, H Weiss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1994
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancerP M Ravdin, A K Tandon, D C Allred, et al.
Human Pathology|September 1, 1992
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancerD C Allred, G M Clark, R Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group StudyR M Elledge, S Green, D Ciocca, et al.
Breast Cancer Research and Treatment|January 1, 1993
The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domainS A Fuqua, D C Allred, R M Elledge, et al.
Cancer Research|January 15, 1992
Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumorsS A Fuqua, S D Fitzgerald, D C Allred, et al.
Cancer Research|August 17, 2000
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesionsS A Fuqua, C Wiltschke, Q X Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1992
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinomaD C Allred, G M Clark, A K Tandon, et al.
Virchows Archiv : an International Journal of Pathology|January 1, 1994
p53 mutations in gastric and colorectal cancers in Texas Hispanics versus AnglosB G Schneider, S G Hilsenbeck, C H Hensel, et al.
Pageof 8